Advertisement

Topics

Latest "Allele Biotechnology Pharmaceuticals" News Stories

18:59 EST 15th February 2019 | BioPortfolio

Here are the most relevant search results for "Allele Biotechnology Pharmaceuticals" found in our extensive news archives from over 250 global news sources.

More Information about Allele Biotechnology Pharmaceuticals on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Allele Biotechnology Pharmaceuticals for you to read. Along with our medical data and news we also list Allele Biotechnology Pharmaceuticals Clinical Trials, which are updated daily. BioPortfolio also has a large database of Allele Biotechnology Pharmaceuticals Companies for you to search.

Showing "Allele Biotechnology Pharmaceuticals" News Articles 1–25 of 14,000+

Extremely Relevant

Allele Biotechnology gets NIH grant to develop sepsis therapies

Allele Biotechnology and Pharmaceuticals has secured grant from the US National Institutes of Health (NIH) unit National Institute of General...Read More... The post Allele Biotechnology gets NIH grant to develop sepsis therapies appeared first on Pharmaceutical Technology.


NIH Awards Grant to Battle Sepsis to San Diego's Allele Biotechnology and Pharmaceuticals

The National Institute of General Medical Sciences, part of the National Institutes of Health, awarded Allele Biotechnology and Pharmaceuticals a Small Business Innovative Research grant to develop therapies for sepsis.

Scientist.com and Allele Biotechnology partner to develop therapeutic nanoantibodies

Scientist.com, the world's leading marketplace for outsourced scientific services, and Allele Biotechnology & Pharmaceuticals Inc., a leading San Diego-based preclinical-stage biopharmaceutical company, have partnered to develop nanoantibodies for therapeutic applications.


NIH Awards Grant to Battle Sepsis to San Diego's Allele Biotechnology and Pharmaceuticals http://dlvr.it/QnPW91 pic.twitter.com/GxCJh3nS7U

NIH Awards Grant to Battle Sepsis to San Diego's Allele Biotechnology and Pharmaceuticals http://dlvr.it/QnPW91  pic.twitter.com/GxCJh3nS7U

Relevant

Scientist.com Partners with Allele Biotech to Discover and Develop Therapeutic Nanoantibodies

Allele uses experts from Scientist.com’s Genius Consulting NetworkTM and proprietary internal technology to create innovative biologics programs Scientist.com, the world's leading marketplace for outsourced scientific services, and Allele Biotechnology & Pharmaceuticals Inc., a leading San Diego-based preclinical-stage biopharmaceutical company, ...

Allele Receives iPSC Patents Bolstering Current Production of Multiple Lines at Wholly Owned cGMP Facility

Allele Biotechnology & Pharmaceuticals Inc. has received issuance notices from the U.S. Patent and Trademark Office for its first batch of patents covering the derivation of induced pluripotent stem cells (iPSCs). Allele’s proprietary technology uses only messenger RNA (mRNA) to reprogram human or other primate cells, avoiding many operational compli...

NIH Awards Allele with Grant for the Development of Nanoantibody Therapies for Treating Sepsis

The National Institute of General Medical Sciences of NIH has awarded a Small Business Innovative Research grant to Allele Biotechnology and Pharmaceuticals to develop new single-domain nanoantibody (nAb) therapies for the treatment of sepsis. Sepsis and septic shock are among the leading causes of death in intensive care units (ICUs). The global incidence...

SELLAS Life Sciences Announces Additional Data Showing Consistent Clinical Effect Across HLA Allele Subgroups in Triple Negative Breast Cancer Patients Treated with Nelipepimut-S Plus Trastuzumab

NEW YORK, Nov. 09, 2018 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced data from a preplanned secondary efficacy analysis across human leukocyte antigen (HLA) allele subgroups from...

Novel multiplex PCR-SSP method for centromeric KIR allele discrimination

Clonality and non-linearity drive facultative-cooperation allele diversity

The FCGR2C allele that modulated the risk of HIV-1 infection in the Thai RV144 vaccine trial is implicated in HIV-1 disease progression

AMAG Pharmaceuticals to Acquire Perosphere Pharmaceuticals

AMAG Pharmaceuticals said today it has agreed to acquire Perosphere Pharmaceuticals for up to $415 million, in a deal that the buyer said will expand its pipeline, and especially its presence in hematology with Perosphere’s next-generation anticoagulant reversal candidate ciraparantag (PER977). Ciraparantag is an intravenously-administered synthetic small molecule anticoagulant reversal agen...

Conatus Pharmaceuticals Inc. (CNAT) Upcoming Presentations, Analysts Review and Target

Conatus Pharmaceuticals, Upcoming Presentations, Analysts Review and Target Traders News Source, a leading independent equity research, and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Conatus Pharmaceuticals Inc. (CNAT), a biotechnology company, focused on the development and commercialization of novel medicines for the treatment of liv...

Alzheimer's Gene Tied to Mental Decline in Older Breast Ca

(MedPage Today) -- Effect seen in systemically treated patients with specific APOE allele

Alzheimer's Disease Biomarkers Differ in African-Americans and White Individuals (CME/CE)

(MedPage Today) -- African-Americans with the APOE-e4 allele have lower tau levels in CSF than whites

Spectrum Pharmaceuticals Receives FDA Approval of Khapzory (levoleucovorin) for Injection

HENDERSON, Nev.--(BUSINESS WIRE)--Oct. 23, 2018-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today...

5 Top Weekly NASDAQ Biotech Stocks: vTv Leads with 374 Percent

vTv Therapeutics, Trevena, Cyclacel Pharmaceuticals, Paratek Pharmaceuticals and Avadel Pharmaceuticals were last week's top gainers on the NASDAQ Biotechnology Index. The post 5 Top Weekly NASDAQ Biotech Stocks: vTv Leads with 374 Percent appeared first on Investing News Network.

5 Top Weekly NASDAQ Biotech Stocks: Genocea Up 56.74 Percent

Genocea Biosciences, EyePoint Pharmaceuticals, Trevena, Adamis Pharmaceuticals and KalVista Pharmaceuticals were last week's top gainers on the NASDAQ Biotechnology Index. The post 5 Top Weekly NASDAQ Biotech Stocks: Genocea Up 56.74 Percent appeared first on Investing News Network.

M&As this week: Telix Pharmaceuticals, PCI Pharma, DZS Clinical Services

Telix Pharmaceuticals Limited has acquired Atlab Pharma SAS for $10m. Based in Australia, Telix is a clinical-stage biotechnology company engaged...Read More... The post M&As this week: Telix Pharmaceuticals, PCI Pharma, DZS Clinical Services appeared first on Drug Development Technology.

Vir Biotechnology, Alnylam Start Phase 1/2 Study Of VIR-2218 - Quick Facts

Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc. (ALNY) said Monday that they have initiated a Phase 1/2 study of VIR-2218, a novel, investigational RNA interference or RNAi therapeutic for the treatment of chronic hepatitis B virus or HBV infection.

SELLAS Life Sciences Announces Additional Data Showing Consistent Clinical Effect Across HLA Allele Subgroups in Triple Negative Breast Cancer (TNBC) Patients Treated with Nelipepimut-S Plus Trastuzumab Presented at the Society for Immunotherapy of Cancer

Final data from Phase 2b clinical trial of nelipepimut-S (NeuVax™) in combination with trastuzumab (Herceptin®) were previously presented at the European Society for Medical Oncology (ESMO) 2018 Annual Meeting Clinically meaningful and statistically significant benefit in the HLA-A24+ subgroup (p=0.003), highly prevalent in the Asian population, with a 90.6% decrease in the relative risk of ...

EyePoint Pharmaceuticals Added to NASDAQ Biotechnology Index

WATERTOWN, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ: NBI). EyePoint’s addition to the NBI will become effective prior to market open on Mo...

Vir Biotechnology, Alnylam Start Phase 1/2 Study Of VIR-2218

WASHINGTON (dpa-AFX) - Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc. (ALNY) said Monday that they have initiated a Phase 1/2 study of VIR-2218, a novel, investigational RNA interferenc...

Rocket Pharmaceuticals to Join NASDAQ Biotechnology Index

Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces that the Company has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ: NBI). Rocket’s addition to the NBI will become effective prior to market open on Monday, December 24, 2018. The N...

X4 Pharmaceuticals Presents Additional Positive Phase 2 Results for X4P 001 in WHIM Syndrome, Continues on Path to Initiation of Phase 3 Trial

CAMBRIDGE, MA – December 1, 2018 – X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 allosteric antagonist drugs to improve immune cell trafficking to treat rare diseases and cancer, today announced the...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks